Publications

A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis

Received: January 15, 2020
Accepted: June 15, 2020
Published online: August 21, 2020

643 S1P/S1PR1 Signalis Required for Optimal T-Cell Pathogenicity to Induce Gvhd By RegulatingDrp1/mTOR Axis

Monday, December 13, 2021: 10:30 AM

S1P Receptor-1 agonist averts the De Novo Generation of Autoreactive T-cells in Murine Acute GVHD

Letter HemeSphere, powered by EHA (Aug-2021)

Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis

Bone Marrow Transplantation – Yokoyama, Teshima et al (2020)

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Frontz Pharmacol
– Perez et al (March 2019)

ASBMT 2018: The Role of S1PR1 Agonism in Thymus-Dependent T-Cell Regeneration and Graft-vs.-Tumor Activity Following Experimental Allogeneic Hematopoietic Stem Cell Transplantation

Vollmer, Krenger (2018)

ASBMT 2018: The Role of S1PR1 Agonism in Thymus-Dependent Generation of Autoreactive T Cells during Experimental Acute Graft-vs.-Host Disease

Vollmer and Krenger (2018)

Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic

Hematopoietic Stem Cell Transplantation, Smith & Gergely (September 2017)

S1P signaling: new therapies and opportunities F1000 Prime reports

Gonzales (December 2014)

Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)

Patricia A. Taylor et al (2007)

GVHD prophylaxis with KRP203, a SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR, is safe and may have a potential to improve

Poster, Heim et al